1
|
JIN X, WU B, WU H, XU D. Effectiveness of Shenshu Guanxin recipe granules for improving exercise tolerance in patients with stable angina pectoris: a randomized, double-blind, placebo-controlled trial. J TRADIT CHIN MED 2023; 43:1227-1233. [PMID: 37946485 PMCID: PMC10623256 DOI: 10.19852/j.cnki.jtcm.20231008.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2022] [Accepted: 05/13/2022] [Indexed: 11/12/2023]
Abstract
OBJECTIVE To assess the effectivess of Shenshu Guanxin recipe granules (, SGR) in improving exercise tolerance and the quality of life in patients with Stable Angina Pectoris (SAP). METHODS A total of 189 patients were consecutively enrolled between December 2012 and December 2014. The included patients were randomly assigned to SGR and placebo groups. The primary endpoints included mainly the results of treadmill exercise test and Seattle Angina Questionnaire (SAQ) during 12 weeks of treatment. RESULTS After 12 weeks of treatment, SGR extended the time of exercise-induced ST-segment depression of 0.1 MV, lowered the maximum ST-segment depression, and shortened the duration of ST-segment depression in patients with SAP in southern China. Besides, the study also proved that SGR could improve the quality of life and functional status of patients with SAP. CONCLUSIONS SGR showed a positive effect on exercise tolerance compared with the placebo besides optimal medical therapy. Also, the study proved that SGR could improve the SAQ score of the patients.
Collapse
Affiliation(s)
- Xiao JIN
- 1 Department of Traditional Chinese Medicine, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Bingxin WU
- 2 Department of Cardiology, Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510000, China
| | - Huanlin WU
- 3 Department of Cardiology, Dongzhimen Hosipital, Beijing 100029, China
| | - Danping XU
- 4 Department of Traditional Chinese Medicine, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China
| |
Collapse
|
2
|
Wang F, Tang L, Liang B, Jin C, Gao L, Li Y, Li Z, Shao J, Zhang Z, Tan S, Zhang F, Zheng S. Yi-Qi-Jian-Pi Formula Suppresses RIPK1/RIPK3-Complex-Dependent Necroptosis of Hepatocytes Through ROS Signaling and Attenuates Liver Injury in Vivo and in Vitro. Front Pharmacol 2021; 12:658811. [PMID: 33967802 PMCID: PMC8102982 DOI: 10.3389/fphar.2021.658811] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 04/07/2021] [Indexed: 12/12/2022] Open
Abstract
Acute-on-chronic liver failure (ACLF) is described as a characteristic of acute jaundice and coagulation dysfunction. Effective treatments for ACLF are unavailable and hence are urgently required. We aimed to define the effect of Yi-Qi-Jian-Pi Formula (YQJPF) on liver injury and further examine the molecular mechanisms. In this study, we established CCl4-, LPS-, and d-galactosamine (D-Gal)-induced ACLF rat models in vivo and LPS- and D-Gal-induced hepatocyte injury models in vitro. We found that YQJPF significantly ameliorates liver injury in vivo and in vitro that is associated with the regulation of hepatocyte necroptosis. Specifically, YQJPF decreased expression of receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3 (RIPK3) and pseudokinase mixed lineage kinase domain-like (MLKL) to inhibit the migration of RIPK1 and RIPK3 into necrosome. YQJPF also reduces the expression of inflammatory cytokines IL-6, IL-8, IL-1β, and TNF-α, which were regulated by RIPK3 mediates cell death. RIPK1 depletion was found to enhance the protective effect of YQJPF. Furthermore, we showed that YQJPF significantly downregulates the mitochondrial reactive oxygen species (ROS) production and mitochondrial depolarization, with ROS scavenger, 4-hydroxy-TEMPO treatment recovering impaired RIPK1-mediated necroptosis and reducing the expression of IL-6, IL-8, IL-1β, and TNF-α. In summary, our study revealed the molecular mechanism of protective effect of YQJPF on hepatocyte necroptosis, targeting RIPK1/RIPK3-complex-dependent necroptosis via ROS signaling. Overall, our results provided a novel perspective to indicate the positive role of YQJPF in ACLF.
Collapse
Affiliation(s)
- Feixia Wang
- Department of Integrated TCM and Western Medicine, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.,Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Li Tang
- Department of Integrated TCM and Western Medicine, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.,Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Baoyu Liang
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Chun Jin
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Liyuan Gao
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Yujia Li
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Zhanghao Li
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Jiangjuan Shao
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Zili Zhang
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Shanzhong Tan
- Department of Integrated TCM and Western Medicine, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.,Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Feng Zhang
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| | - Shizhong Zheng
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| |
Collapse
|
3
|
Yang M, Du T, Sun M, Long H, Li D, Shen Z, Wu Q, Lao L, Liang F. Acupuncture for stable angina pectoris: a systematic review protocol. BMJ Open 2018; 8:e019798. [PMID: 29622575 PMCID: PMC5892774 DOI: 10.1136/bmjopen-2017-019798] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
INTRODUCTION Previous reviews indicate that the effect of acupuncture on stable angina pectoris (SAP) remains controversial. The results of trials published in the past 5 years may possibly change this situation, but an updated systematic review is not available. We therefore designed this study to systematically assess the efficacy and safety of acupuncture for treating SAP. METHODS AND ANALYSIS Nine online databases will be searched without language or publication status restrictions from their inception to September 2017. Randomised controlled trials that include patients with stable angina receiving acupuncture therapy versus a control group will be deemed eligible. The selection of studies, data extraction and risk of bias assessment will be carried out by two independent reviewers. Data synthesis will be performed using RevMan V.5.3 software with either a fixed effects model or random effects model, depending on the heterogeneity test. Evidence quality will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation system. The efficacy-effectiveness spectrum for each included trial will be rated using the Rating of Included Trials on the Efficacy-effectiveness Spectrum tool. Outcomes of interest include the improvement of weekly angina attacks and reduction of nitroglycerin medication use after receiving acupuncture treatment, the incidence of cardiovascular events, heart rate variability, pain intensity measured on a visual analogue scale, total workload and exercise duration at peak exercise, safety and adverse events. A meta-analysis will be conducted if no considerable heterogeneity is detected. The results will be presented as risk ratios with 95% CIs for dichotomous data and weighted mean differences or standardised mean differences with 95% CIs for continuous data. ETHICS AND DISSEMINATION This systematic review will not involve private information from individuals or endanger their rights, and therefore does not necessarily require ethical approval. The results may be published in a peer-reviewed journal or disseminated in relevant conferences. TRIAL REGISTRATION NUMBER CRD42015016201.
Collapse
Affiliation(s)
- Mingxiao Yang
- School of Chinese Medicine, University of Hong Kong, Hong Kong
| | - Ting Du
- Department of Rehabilitation, Xishan People's Hospital of Wuxi Municipality, Wuxi, China
| | - Mingsheng Sun
- School of Acupuncture and Tuina, Chengdu University of TCM, Chengdu, China
| | - Hulin Long
- Department of Acupuncture and Rehabilitation, Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Dehua Li
- Department of Acupuncture and Rehabilitation, Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Zhifu Shen
- School of Acupuncture and Tuina, Chengdu University of TCM, Chengdu, China
| | - Qiaofeng Wu
- School of Acupuncture and Tuina, Chengdu University of TCM, Chengdu, China
| | - Lixing Lao
- School of Chinese Medicine, University of Hong Kong, Hong Kong
| | - Fanrong Liang
- School of Acupuncture and Tuina, Chengdu University of TCM, Chengdu, China
| |
Collapse
|
4
|
Li L, Liu N, Dai X, Yan H, Zhang L, Xing L, Wang Y, Wang Y. Development of a dual screening strategy to identify pro-angiogenic compounds from natural products: application on Tongmai Yangxin Pills. RSC Adv 2016. [DOI: 10.1039/c6ra19212b] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Establishment and application the dual-screening strategy to screen pro-angiogenic compounds from natural products for the first time.
Collapse
Affiliation(s)
- Lailai Li
- Institute of Traditional Chinese Medicine Research
- Key Laboratory of Formula of Traditional Chinese Medicine
- Tianjin State Key Laboratory of Modern Chinese Medicine
- Tianjin University of Traditional Chinese Medicine
- Tianjin 300193
| | - Ningning Liu
- Institute of Traditional Chinese Medicine Research
- Key Laboratory of Formula of Traditional Chinese Medicine
- Tianjin State Key Laboratory of Modern Chinese Medicine
- Tianjin University of Traditional Chinese Medicine
- Tianjin 300193
| | - Xiangdong Dai
- Institute of Traditional Chinese Medicine Research
- Key Laboratory of Formula of Traditional Chinese Medicine
- Tianjin State Key Laboratory of Modern Chinese Medicine
- Tianjin University of Traditional Chinese Medicine
- Tianjin 300193
| | - Haifeng Yan
- Institute of Traditional Chinese Medicine Research
- Key Laboratory of Formula of Traditional Chinese Medicine
- Tianjin State Key Laboratory of Modern Chinese Medicine
- Tianjin University of Traditional Chinese Medicine
- Tianjin 300193
| | - Ling Zhang
- The Second Affiliated Hospital Zhejiang University School of Medicine
- Zhejiang University
- Hangzhou 310058
- China
| | - Leilei Xing
- Institute of Traditional Chinese Medicine Research
- Key Laboratory of Formula of Traditional Chinese Medicine
- Tianjin State Key Laboratory of Modern Chinese Medicine
- Tianjin University of Traditional Chinese Medicine
- Tianjin 300193
| | - Yi Wang
- College of Pharmaceutical Sciences
- Zhejiang University
- Hangzhou 310058
- China
| | - Yi Wang
- Institute of Traditional Chinese Medicine Research
- Key Laboratory of Formula of Traditional Chinese Medicine
- Tianjin State Key Laboratory of Modern Chinese Medicine
- Tianjin University of Traditional Chinese Medicine
- Tianjin 300193
| |
Collapse
|
5
|
Wang PQ, Li DD, Dong W, Liu J, Yu YN, Shen CT, Chen QG, Chen BW, Chen YD, Wang Z. Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial. Trials 2015; 16:474. [PMID: 26489511 PMCID: PMC4618746 DOI: 10.1186/s13063-015-0998-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Accepted: 10/05/2015] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Chronic stable angina is a leading cause of death worldwide. Danhong injection, a complementary alternative medicine for chronic stable angina, has been demonstrated to be effective in numerous studies and is widely prescribed to patients. However, the methodological quality of most prior studies was found to be, in general, low. Therefore, we designed this randomized controlled trial to evaluate the efficacy and safety of using Danhong injection to treat chronic stable angina. METHODS/DESIGN This is a randomized multicentre, double-blind, placebo-controlled, adaptive clinical trial. A total of 870 patients meeting the eligibility criteria will be randomly assigned into either the Danhong injection or the placebo group in a 2:1 ratio. Participants will then undergo a 2-week treatment regimen and a 76-day follow-up period. Because this is an adaptive trial, two interim analyses are prospectively planned. These will be performed after one-third and two-thirds of the patients, respectively, have completed the trial. Based on the results of these interim analyses, a data monitoring committee will determine how to modify aspects of the study without undermining the validity and integrity of the trial. The primary outcome measure is the proportion of patients who show a clinically significant change, which is defined as at least a 20-point improvement in angina frequency score on the Seattle Angina Questionnaire, which will be administered on day 30. Other secondary efficacy and safety outcomes will also be assessed. DISCUSSION This trial will provide high-quality evidence regarding the use of Danhong injection to treat chronic stable angina. TRIAL REGISTRATION ClinicalTrials.gov: NCT01681316 .
Collapse
Affiliation(s)
- Peng Qian Wang
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie, Dongzhimen nei, Beijing, 100700, China.
| | - Dan Dan Li
- Department of Cardiology, PLA General Hospital, Beijing, 100853, China.
| | - Wei Dong
- Department of Cardiology, PLA General Hospital, Beijing, 100853, China.
| | - Jun Liu
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie, Dongzhimen nei, Beijing, 100700, China.
| | - Ya Nan Yu
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie, Dongzhimen nei, Beijing, 100700, China.
| | - Chun Ti Shen
- Changzhou Traditional Chinese Medicine Hospital, Heping North Road, Changzhou, 213004, Jiangsu, China.
| | - Qi Guang Chen
- School of Public Health, Southeast University, Dijia Qiao 87, Nanjing, 210009, Jiangsu, China.
| | - Bing Wei Chen
- School of Public Health, Southeast University, Dijia Qiao 87, Nanjing, 210009, Jiangsu, China.
| | - Yun Dai Chen
- Department of Cardiology, PLA General Hospital, Beijing, 100853, China.
| | - Zhong Wang
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie, Dongzhimen nei, Beijing, 100700, China.
| |
Collapse
|